| Literature DB >> 28272780 |
Hongbo Zhang1,2, Dongfei Liu1, Liang Wang3, Zehua Liu1, Runrun Wu4, Agne Janoniene5, Ming Ma6, Guoqing Pan7, Lina Baranauskiene5, Linlin Zhang6, Wenguo Cui7, Vilma Petrikaite5,8, Daumantas Matulis5, Hongxia Zhao3, Jianming Pan4,9, Hélder A Santos1.
Abstract
Structural features of nanoparticles have recently been explored for different types of applications. To explore specific particles as nanomedicine and physically destroy cancer is interesting, which might avoid many obstacles in cancer treatment, for example, drug resistance. However, one key element and technical challenge of those systems is to selectively target them to cancer cells. As a proof-of-concept, Prickly zinc-doped copper oxide (Zn-CuO) nanoparticles (Prickly NPs) have been synthesized, and subsequently encapsulated in a pH-responsive polymer; and the surface has been modified with a novel synthesized ligand, 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl] benzenesulfonamide (VD1142). The Prickly NPs exhibit very effective cancer cell antiproliferative capability. Moreover, the polymer encapsulation shields the Prickly NPs from unspecific nanopiercing and, most importantly, VD1142 endows the engineered NPs to specifically target to the carbonic anhydrase IX, a transmembrane protein overexpressed in a wide variety of cancer tumors. Intracellularly, the Prickly NPs disintegrate into small pieces that upon endosomal escape cause severe damage to the endoplasmic reticulum and mitochondria of the cells. The engineered Prickly NP is promising in efficient and targeted cancer treatment and it opens new avenue in nanomedication.Entities:
Keywords: Zn-doped CuO; acetalated dextran; microfluidic; mitochondria; targeted cancer therapy
Mesh:
Substances:
Year: 2017 PMID: 28272780 DOI: 10.1002/adhm.201601406
Source DB: PubMed Journal: Adv Healthc Mater ISSN: 2192-2640 Impact factor: 9.933